HALO Program Update

November 28, 2022

Forward Looking Statements Disclaimer

This presentation contains certain forward-looking statements, including, but not limited to, statements related to CinCor's business in general; the development and commercial potential of baxdrostat; expectations with respect to the planned end of Phase 2 meeting with the FDA and the anticipated timing thereof; expectations with respect to the Company's ongoing open label extension trial, ongoing clinical trials and planned Phase 3 trials, including the timing and results thereof; the therapeutic potential of baxdrostat (CIN-107), including its potential to be an effective treatment for patients with treatment-resistant hypertension, uncontrolled hypertension, CKD and primary aldosteronism, and the ability of baxdrostat to address multiple unmet needs in patients; and other statements that are not historical facts. Because such statements are subject to risks and uncertainties, actual results may differ from those expressed or implied by such forward-looking statements. Words such as "anticipates," "believes," "expected," "intends," "plan," "may", "will," "project", "estimate", "continue," and "future" or similar expressions are intended to identify forward-looking statements. These forward-looking statements are based on CinCor's current plans, objectives, estimates, expectations and intentions, involve assumptions that may never materialize or may prove to be incorrect and inherently involve significant risks and uncertainties, including factors beyond CinCor's control, that could cause actual results, performance, or achievement to differ materially and adversely from those anticipated or implied in the statements, including, without limitation, CinCor has incurred significant operating losses since its inception; CinCor has a limited operating history and no history of commercializing products; CinCor will require substantial additional funding to finance its operations; CinCor's business is entirely dependent at this time on the success of one drug, baxdrostat; initial, interim, "top-line" and preliminary data from clinical trials announced or published from time to time may change; CinCor may not be successful in its efforts to expand its pipeline beyond baxdrostat; success in preclinical studies or earlier clinical trials may not be indicative of results in future clinical trials; enrollment and retention of patients in clinical trials could be delayed; CinCor relies and will rely on third parties to conduct, supervise and monitor

existing clinical trials and potential future clinical trials; developments from the company's competitors and the marketplace for the company's products; and

CinCor's business, operations and clinical development timelines and plans may be adversely affected by the evolving and ongoing COVID-19 pandemic, geopolitical events, including the ongoing military conflict between Russia and Ukraine and related sanctions against Russia, and macroeconomic conditions, including rising inflation and interest rates and uncertain credit and financial markets, and matters related thereto; and other risks and uncertainties affecting the company, including those described under the caption "Risk Factors" and elsewhere in CinCor's Annual Report on Form 10-K for the year ended December 31, 2021 filed with the Securities and Exchange Commission (SEC) on March 22, 2022, CinCor's Quarterly Report on Form 10-Q for the three months ended March 31, 2022 filed with the SEC on May 10, 2022, CinCor's Quarterly Report on Form 10-Q for the three months ended June 30, 2022 filed with the SEC on August 8, 2022, CinCor's Quarterly Report on Form 10-Q for the three months ended September 30, 2022 filed with the SEC on November 3, 2022, and other filings and reports that CinCor may file from time to time with the SEC. Other risks and uncertainties of which CinCor is not currently aware may also affect the company's forward-looking statements and may cause actual results and the timing of events to differ materially from those anticipated. All forward-looking statements contained in this presentation speak only as of the date on which they were made and are based on management's assumptions and estimates as of such date. CinCor undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required by law.

CinCor Overview 2

HALO Program Update

Phase 2 HALO trial in patients with uncontrolled hypertension

Missed primary endpoint of reduction in SBP at 8 weeks, but CinCor believes key learnings support progression into planned Phase 3 program:

  • 12.6 mmHg reduction in pre-specified subgroup of Non-Hispanic/Latinos
  • Safety and tolerability profile observed in HALO was similar to profile observed in treatment resistant hypertensive (rHTN) patients in BrigHtn trial
  • No patient discontinued due to treatment-related adverse events

CinCor Overview 3

Objectives of HALO Phase 2 Study: uHTN* Population

Informing target population and doses for planned Phase 3 program

HALO

Placebo controlled, dose range finding in uHTN* population on 1 - 2 anti-hypertensive medications

30-35 MILLION PATIENTS with uHTN in the U.S.

Unmet medical need but payers will likely require differentiation to gain appropriate placement and reimbursement

Key Objectives

Does baxdrostat work in uHTN patients?

What doses produce robust blood pressure (BP) lowering?

Are there sub-groups of patients who respond better than others, and if yes:

  • Was response defined by background BP meds effect?
  • Did levels of aldosterone or renin predict response?
  • Did demographic or race/ethnic characteristics contribute to response?

*uHTN: uncontrolled hypertension

CinCor Overview 4

HALO Phase 2 Trial in uHTN* - 249 Patients Randomized

>85% of HALO completers enrolled in the ongoing Open Label Extension (OLE) trial**

Key Inclusion Criteria

Primary Endpoint (Part 1, 8 weeks)

• On a stable regimen of anti-hypertensive agents for at least 8 weeks

•

Change from baseline in mean seated systolic BP

• Seated BP ≥ 140 mmHg

Key Exclusion Criteria

Key Secondary Endpoints

• Seated SBP ≥ 180 mmHg

• Change from baseline in mean seated diastolic BP

• Estimated glomerular filtration rate (eGFR) < 30 mL/min/1.73m2

•

The percentage of patients achieving a seated BP response <130 mmHg

2-4-weeks

8-weeks

4-weeks

Screening

Run-In

Part 1: QD Double-Blind Treatment

Part 2: QD Single Blind

Safety/OLE

0.5 mg

Single-blind run-

Follow-Up

Stable medication

1 mg

2 mg

in to assess

(2 weeks) or enroll

regimen

2 mg

adherence

in OLE

Placebo

Remain on background anti-hypertensive medication(s)

Remove background Tx

249 Randomized -> 227 Completers of Part 1

Patient Flow

213 Randomized -> 201 Completers

175 Randomized***

*uHTN: uncontrolled hypertension, estimate does not include rHTN patients

  • 201 patients completed HALO and 170 of those elected to participate in the OLE (170/201=85%)
  • 5 patients from Part 1 that did not qualify for Part 2 and were not HALO completers elected to enroll in the OLE yielding 175 patients

CinCor Overview 5

This is an excerpt of the original content. To continue reading it, access the original document here.

Attachments

  • Original Link
  • Original Document
  • Permalink

Disclaimer

CinCor Pharma Inc. published this content on 28 November 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 28 November 2022 12:44:06 UTC.